CardioPrecision is proud to announce that it has received a nomination for an award at the Scotland’s Life Sciences Annual Awards.

CardioPrecision is one of three finalists under the Innovation – Health technology Category.

Scotland’s Life Sciences Annual Awards recognise the outstanding achievements of individuals, companies & research organisations within the sector. The innovation in Health Technology award will be presented to an organisation that has been responsible for the creation of an innovative product or service that is contributing real value to the healthcare.

Dr Ying Sutherland, CEO of CardioPrecision, commented: “We are delighted to receive this nomination. To be considered for this award is a great honour and a privilege.  It validates the tireless endeavours and achievements by everyone in the team during our journey till now”

CardioPrecision is a MedTech company with medical devices for less invasive treatment of structural heart disease and cardiothoracic interventions. Since spinning out of the NHS, CardioPrecision has developed a platform technology. Initially the company principally focused on the innovative transcervical approach for minimally invasive aortic valve surgery and interventions. In 2021, at the height of the COVID pandemic, it launched its suite of CoreVista® devices for use in Endoscopic Vessel Harvesting (EVH) during coronary artery bypass grafting (CABG) surgery, a world-first for bringing a plug-and-play high-definition screen into the operative field within direct sight and control of the EVH operator. These products are now being adopted in both NHS hospitals and private healthcare sector.

CardioPrecision’s patented technology could potentially be applied to a wider range of cardiothoracic procedures and the company is dedicated to making patients’ lives better through the development of innovative and less invasive solutions for cardiothoracic surgery and cardiovascular interventions.

The awards will be presented at a celebration dinner on 16 March 2023 at the National Museum of Scotland, Edinburgh.


About CardioPrecision Ltd

CardioPrecision Ltd, based in Glasgow, UK is the global leader in transcervical access for the treatment of structural heart disease and cardiothoracic interventions.  CardioPrecision is dedicated to making patients’ lives better through the development of innovative, less invasive solutions for cardiothoracic surgery and cardiovascular interventions.  For more information, visit


About Scottish Life Sciences Award

Scotland’s Life Sciences Annual Awards showcase eight prestigious awards recognising a range of achievements including skills development, innovation, investment, innovative collaboration, and business leadership.


This news release includes forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding expected product benefits, anticipated product approvals, future plans related to the product lines, the benefits of the transaction, including future financial and operating results, objectives and expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of the company and are subject to significant risks and uncertainties. 

Actual future events or results may differ materially from these statements as a result of various factors, including: unexpected costs of device development and approvals, unanticipated outcomes after more expanded pre-clinical and clinical experience with the devices, unexpected changes or delays related to product supply, potentials for unexpected regulatory or quality delays or developments, competitive dynamics, global economic conditions and customer acceptance, and other economic, business, and/or competitive factors. The forward-looking statements speak only as of the date of this communication. Except as required by law, The Company undertakes no obligation to update these statements.


CoreVista is a trademark of CardioPrecision Ltd.